The Pemphigus Vulgaris drugs in development market research report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pemphigus Vulgaris. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Pemphigus Vulgaris by 11 companies/universities/institutes. The top development phase for Pemphigus Vulgaris is preclinical with seven drugs in that stage. The Pemphigus Vulgaris pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pemphigus Vulgaris pipeline products market are: Cabaletta Bio, Artiva Biotherapeutics and ImmunoWork.
The key targets in the Pemphigus Vulgaris pipeline products market include B Lymphocyte Antigen CD19, B Lymphocyte Antigen CD20, and Desmoglein 1.
The key mechanisms of action in the Pemphigus Vulgaris pipeline product include B Lymphocyte Antigen CD20 Inhibitor with two drugs in Preclinical. The Pemphigus Vulgaris pipeline products include three routes of administration with the top ROA being Intravenous and six key molecule types in the Pemphigus Vulgaris pipeline products market including Gene-Modified Cell Therapy, and Monoclonal Antibody.
Pemphigus Vulgaris overview
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender, and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, and skin blisters that come and go. The blisters always occur near the surface of the skin and there is oozing, crusting, or peeling at the blister site.
For a complete picture of Pemphigus Vulgaris’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
